Stage
No active trials
Next date
None yet
Trials
0 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CT-P43, 45 mg in 0.5 ml, a single subcutaneous (SC) injection via pre-filled syringe (PFS)”In the company’s words, NCT06951828 on ClinicalTrials.gov
- Tested for
- Psoriasis
- Main trialPhase 3
- “This study is a randomized, active-controlled, double-blind, phase 3 study to compare the efficacy and safety of CT-P43 to Stelara in patients with moderate to severe plaque psoriasis.”In the company’s words, NCT04673786 on ClinicalTrials.gov
- Copy of
- Stelara (Centocor Ortho Biotech Inc)Tested side by side with the original in NCT04428814, NCT04673786
Other drugs for Psoriasis
- ZasocitinibTakeda · Phase 3
- TQH3906Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- PiclidenosonCan-Fite BioPharma · Phase 3
- Total coumarin creamPsoriasis Research Institute of Guangzhou · Phase 3
- RisankizumabAbbVie · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 4 Aug 2021 | A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis | |
| Phase 1Completed | 24 Feb 2021 | Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects | |
| Phase 1Completed | 26 Nov 2025 | A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P43 in Healthy Male Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026